{"id":"efz-emt-tdf","safety":{"commonSideEffects":["dizziness","nausea","headache","fatigue","rash","abnormal dreams"],"contraindications":["hypersensitivity to efavirenz, emtricitabine, tenofovir, or any component"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"HIV-1 reverse transcriptase","explanation":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase. Emtricitabine and tenofovir are nucleoside/nucleotide analogs that competitively inhibit HIV reverse transcriptase and terminate viral DNA chain elongation. The combination provides synergistic antiviral activity through complementary mechanisms.","oneSentence":"Combines an NNRTI, nucleoside reverse transcriptase inhibitor, and nucleotide reverse transcriptase inhibitor to block HIV replication at multiple steps."},"_scrapedAt":"2026-03-28T04:36:50.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123481,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"efavirenz/emtricitabine/tenofovir disoproxil fumarate","brand":"Atripla","company":"Bristol-Myers Squibb/Gilead Sciences","rationale":"Same three-drug fixed-dose combination for HIV-1 treatment"},{"name":"bictegravir/emtricitabine/tenofovir alafenamide","brand":"Biktarvy","company":"Gilead Sciences","rationale":"Single-tablet regimen for HIV-1 with improved tenofovir formulation"},{"name":"dolutegravir/lamivudine","brand":"Dovato","company":"ViiV Healthcare","rationale":"Two-drug fixed-dose combination for HIV-1 treatment"}],"description":"EFZ EMT TDF is a fixed-dose combination antiretroviral therapy in Phase 1 development by Sanofi. It combines efavirenz (EFZ), emtricitabine (EMT), and tenofovir disoproxil fumarate (TDF) for potential treatment of HIV-1 infection. This triple-drug regimen aims to simplify dosing by combining three established antiretroviral agents into a single formulation.","indications":{"approved":[{"status":"investigational","condition":"HIV-1 infection","patientPopulation":"Adult patients, first-line therapy"}]},"trialDetails":[{"nctId":"NCT01690403","phase":"PHASE1","title":"Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Tuberculosis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ATRIPLA™"],"phase":"phase_1","status":"active","brandName":"EFZ EMT TDF","genericName":"EFZ EMT TDF","companyName":"Sanofi","companyId":"sanofi","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2007-12-13T00:00:00.000Z","mah":"Gilead Sciences Ireland UC","brand_name_local":"Atripla","application_number":"EMEA/H/C/000797"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}